NHWK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (5 Feb 2024 @ 21:58):

Stats
Tagesvolumen	161 222
Durchschnittsvolumen	163 739
Marktkapitalisierung	10.78M
EPS	$0 ( 2024-03-29 )
Nächstes Ertragsdatum	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.202
ATR14	$0.0430 (13.71%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-07	Wolf Jeffrey Alan	Buy	2 843 137	Stock Option (right to buy)
2022-12-07	Smith Edward B Iii	Buy	101 960	Stock Option (right to buy)
2022-12-07	Prendergast John K A	Buy	203 921	Stock Option (right to buy)
2022-12-07	Ostrander William L.	Buy	490 196	Stock Option (right to buy)
2022-12-07	Monahan John J	Buy	101 960	Stock Option (right to buy)

INSIDER POWER
100.00
Last 95 transactions
Buy: 24 129 486 \| Sell: 659 541

Volumen Korrelation

Lang: -0.20 (neutral)

Kurz: -0.48 (neutral)

Signal:(40.526) Neutral

NightHawk Biosciences, Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

NightHawk Biosciences, Korrelation - Währung/Rohstoff

-0.39
( neutral )

-0.46
( neutral )

0.00
( neutral )

-0.50
( weak negative )

-0.39
( neutral )

0.05
( neutral )

NightHawk Biosciences, Finanzdaten

Annual	2022
Umsatz:	$5.98M
Bruttogewinn:	$-420 025 (-7.02 %)
EPS:	$-1.710

FY	2022
Umsatz:	$5.98M
Bruttogewinn:	$-420 025 (-7.02 %)
EPS:	$-1.710

FY	2021
Umsatz:	$2.11M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.410

FY	2020
Umsatz:	$2.95M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.630

Financial Reports:

No articles found.

NightHawk Biosciences,

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.